Momelotinib
Momelotinib is the JAK inhibitor designed for anaemic myelofibrosis patients: it can improve haemoglobin while shrinking the spleen.
MOMENTUM (2023) versus danazol in symptomatic anaemic patients after a JAK inhibitor: superior symptom response, non-inferior transfusion independence, better spleen response. SIMPLIFY-1/2 earlier trials. Approved 2023 (US), 2024 (EU).
- Medicare
- Part D (self-administered)
Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026).
- Commercial insurance
- covered with prior authorisation
Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy. Myelofibrosis with anaemia documented.
- Assistance programmes
- Together with GSK Oncology
- PAN Foundation — Disease-specific co-pay and premium funds; open and closed funds change monthly.
- HealthWell Foundation
- CancerCare Co-Payment Assistance Foundation
- Patient Advocate Foundation Co-Pay Relief
- Leukemia & Lymphoma Society financial support
Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.
Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.
- Notes
- Licensed 2024 for myelofibrosis with anaemia; NICE recommended it in 2024. TA number not verified.
Sources: NICE search: momelotinib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2023 | Intermediate/high-risk myelofibrosis with anaemia |
| EU | 2024 | Myelofibrosis with moderate-to-severe anaemia |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
MOMENTUM addressed the biggest gap left by ruxolitinib: patients whose anaemia makes standard JAK inhibition hard to give. Momelotinib is now the preferred option for anaemic, previously treated myelofibrosis and is being adopted in first line for anaemic patients. The absolute symptom benefit is modest and durable disease modification has not been shown.
COMFORT-I turned the 2005 discovery of the JAK2 V617F mutation into the first effective medicine for myelofibrosis, transforming symptom control for a disease with no prior standard. Ruxolitinib is still the reference first-line therapy, with fedratinib, pacritinib and momelotinib as alternatives for cytopenic patients. It does not eliminate the malignant clone or reverse fibrosis in most patients.
Latest papers
topQuery for this drug: (TITLE:"Momelotinib" OR ABSTRACT:"Momelotinib" OR TITLE:"Ojjaara" OR ABSTRACT:"Ojjaara" OR TITLE:"Omjjara" OR ABSTRACT:"Omjjara") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Momelotinib, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductPacritinib
Shares MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, JAK2, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag gap-fill.
- ProductFedratinib
Shares COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, JAK2, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag gap-fill.
- ProductRuxolitinib
Shares MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor, COMFORT-I: ruxolitinib, the first JAK inhibitor, versus placebo for myelofibrosis, JAK2, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag gap-fill.
- ProductRopeginterferon alfa-2b
Shares JAK2, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag gap-fill.
- ProductRusfertide
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tag gap-fill.
- TargetMDM2
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tag gap-fill.
- ProductEnsartinib
Shares Small-molecule kinase inhibitors and the tag gap-fill.
- ProductDacomitinib
Shares Small-molecule kinase inhibitors and the tag gap-fill.